Mary Eileen Dolan to Genome, Human
This is a "connection" page, showing publications Mary Eileen Dolan has written about Genome, Human.
Connection Strength
2.735
-
Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics. 2012 Jul; 22(7):498-507.
Score: 0.303
-
Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. Pharmacogenomics. 2010 Apr; 11(4):471-4.
Score: 0.259
-
Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery. Pharmacogenomics. 2010 Feb; 11(2):249-56.
Score: 0.256
-
Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum Genomics. 2009 Jan; 3(2):128-42.
Score: 0.238
-
Genetic architecture of transcript-level variation in humans. Am J Hum Genet. 2008 May; 82(5):1101-13.
Score: 0.226
-
Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet. 2007 Sep; 81(3):427-37.
Score: 0.215
-
Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 2007 Jun 01; 67(11):5425-33.
Score: 0.213
-
Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res. 2017 Aug 01; 23(15):4010-4019.
Score: 0.106
-
Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 2014 Apr; 10(4):e1004192.
Score: 0.085
-
Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits. Genetics. 2013 Aug; 194(4):987-96.
Score: 0.081
-
Relating human genetic variation to variation in drug responses. Trends Genet. 2012 Oct; 28(10):487-95.
Score: 0.076
-
Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011; 6(7):e21920.
Score: 0.071
-
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011 Aug 15; 17(16):5490-500.
Score: 0.071
-
Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 2011; 12(5):R46.
Score: 0.070
-
A pharmacogene database enhanced by the 1000 Genomes Project. Pharmacogenet Genomics. 2009 Oct; 19(10):829-32.
Score: 0.063
-
Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. RNA Biol. 2009 Sep-Oct; 6(4):412-25.
Score: 0.062
-
Identification of common genetic variants that account for transcript isoform variation between human populations. Hum Genet. 2009 Feb; 125(1):81-93.
Score: 0.059
-
Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations. Pharmacogenomics. 2008 May; 9(5):489-92.
Score: 0.057
-
Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics. 2007 Sep; 8(9):1159-68.
Score: 0.054
-
Genome scan implicates adhesion biological pathways in secondary leukemia. Leukemia. 2007 Oct; 21(10):2128-36.
Score: 0.054
-
Efficient expression of foreign genes in human CD34(+) hematopoietic precursor cells using electroporation. Gene Ther. 2001 Mar; 8(5):384-90.
Score: 0.034
-
Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity. Pharmacogenomics J. 2019 04; 19(2):178-190.
Score: 0.028
-
Identification and validation of genetic variants that influence transcription factor and cell signaling protein levels. Am J Hum Genet. 2014 Aug 07; 95(2):194-208.
Score: 0.022
-
Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010 Apr 01; 6(4):e1000888.
Score: 0.016
-
Comprehensive survey of SNPs in the Affymetrix exon array using the 1000 Genomes dataset. PLoS One. 2010 Feb 23; 5(2):e9366.
Score: 0.016